Founder and senior advisor
Isofol Medical AB was founded in 2008 and was based on a research partnership between Professor Bengt Gustavsson and Merck & Cie, the world’s leading manufacturers of folate-based therapies. In 1978, the research team discovered that the folate-based treatment, leucovorin (LV), significantly increased the effect of the cytotoxic antimetabolite, fluorouracil (5-FU). This discovery subsequently led to the 5-FU/LV combination that now lies at the core of colorectal cancer treatment.
Professor Gustavsson formulated the hypothesis that the reason why only a few of his patients responded fully to the leucovorin treatment was their reduced genetic ability to effectively use key enzymes involved in folate metabolism.
A developmental programme in which the active component of arfolitixorin could be tested clinically was designed in order to confirm the original hypothesis. The programme was expensive and Isofol Medical AB was founded, in order to finance the development work and enable any potential commercialisation, by Professor Gustavsson and Yield Life Science (publ.) and the company has since 2008 gained new shareholders in the hope of realizing the vision of improving the effect and reducing the side effects of cancer treatment with antimetabolites. The company’s shares traded on Nasdaq Stockholm´s main market in the Mid Cap segment.
Professor Gustavsson is now a senior advisor to Isofol when it comes to research on folates.
Last updated 07-04-2022